Screener
Xenon Pharmaceuticals XENE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's EPS (diluted)?
- Xenon Pharmaceuticals (XENE) reported EPS (diluted) of -$1.11 in Q2 2026.
- How has Xenon Pharmaceuticals's EPS (diluted) changed year-over-year?
- Xenon Pharmaceuticals's EPS (diluted) decreased by 3.7% year-over-year, from -$1.07 to -$1.11.
- What is the long-term trend for Xenon Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's EPS (diluted) has grown at a 25.3% compound annual growth rate (CAGR), from -$1.77 to -$4.36.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Xenon Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude